Aging and Disease
Frailty linked to faster decline during lecanemab therapy
Patients with physical frailty worsened 1.52 points per year faster on a dementia severity scale than those without frailty while receiving lecanemab.Patients with physical frailty worsened 1.52 points per year faster on a dementia severity scale than those without frailty while receiving lecanemab.
Cohort · 187 peopleBiomarkers
Who was studied187 people with amyloid-positive early Alzheimer's disease
What changedDementia severity worsened 1.52 points per year faster in patients with frailty than those without frailty during lecanemab treatment
The catchOnly 187 patients were included, and the authors called for validation in larger cohorts